Patent ID: 6171796
Filing Date: 2001-01-09
Classification: C12Q,G01N,Y10S

Abstract:
A method of diagnosing metastatic prostate cancer in a subject, comprising the steps of:(a) obtaining one or more test samples from prostate tissue or serum or both of said subject; and(b) detecting a decrease in the amount of polypeptide expressed from a metastatic prostate cancer marker gene selected from prostate-specific transglutaminase, cytokeratin 15, or semenogelin II or a combination thereof in said test samples;wherein a decrease in the expression of prostate-specific transglutaminase or cytokeratin 15 polypeptide in a test sample from prostate tissue or of semenogelin II polypeptide in a test sample from serum is diagnostic for metastatic prostate cancer.